Gilead Sciences (GILD) Tops Q3 EPS by 16c, Remdesivir Revenue $873M in Qtr; Lowers FY EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Gilead Sciences Announces Third Quarter 2020 Financial Results
October 28, 2020 4:01 PM EDTThird Quarter 2020 Highlights: Year-Over-Year
- Product Sales increased 18% to $6.5 billion -
- Product Sales excluding Veklury increased 2% to $5.6 billion -
-Â GAAP Diluted EPS of $0.29 -
-Â Non-GAAP Diluted EPS increased 29% to $2.11 -
-Â Acquisition of Immunomedics, Inc. -
Updated Full Year 2020 Guidance
-Â Product Sales of $23 billion to $23.5 billion -
-... More
